Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin

Leithner, Andreas; Schnack, Beate; Katterschafka, Thomas; Wiltschke, Christoph; Amann, Gabriele; Windhager, Reinhard; Kotz, R.; Zielinski, Christoph

doi:10.1002/(sici)1096-9098(200001)73:1<21::aid-jso6>3.0.co;2-g

Cited by 59 publications

(34 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NCCN guidelines include anti-inflammatory agents (celecoxib, sulindac), anti-hormonal agents (tamoxifen, interferons), tyrosine kinase inhibitors (imatinib, sorafenib) and chemotherapy agents (doxorubicin, vinblastine, methotrexate), to be used in cases of advanced, surgically unresectable disease or in patients that are not surgical candidates due to co-morbid conditions [27][28][29][30][31][32][33].…”

Section: Discussionmentioning

confidence: 99%

Robotic-Assisted Distal Pancreatectomy for a Pancreatic Desmoid Tumor: A Case Report and Review of the Literature

Younan¹,

Oshima²,

Ballard³

et al. 2017

Med Case Rep

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Robotic-Assisted Distal Pancreatectomy for a Pancreatic Desmoid Tumor: A Case Report and Review of the Literature

Younan¹,

Oshima²,

Ballard³

et al. 2017

Med Case Rep

View full text Add to dashboard Cite

show abstract

“…Such a function can explain the disappointing results of some clinical trials of IFN despite suggestive in vitro data. Treatment of aggressive fibromatosis tumors with IFN has been reported in isolated cases (47)(48)(49)(50) with variable results. Our data show disparate roles for IFN signaling in aggressive fibromatosis, a finding which explains the variable clinical results in these case reports.…”

Section: Discussionmentioning

confidence: 99%

IFN-β Signaling Positively Regulates Tumorigenesis in Aggressive Fibromatosis, Potentially by Modulating Mesenchymal Progenitors

et al. 2007

View full text Add to dashboard Cite

Aggressive fibromatosis (also called desmoid tumor) is a benign, locally invasive, soft tissue tumor composed of cells with mesenchymal characteristics. These tumors are characterized by increased levels of B-catenin-mediated T-cell factor (TCF)-dependent transcriptional activation. We found that type 1 IFN signaling is activated in human and murine aggressive fibromatosis tumors and that the expression of associated response genes is regulated by B-catenin. When mice deficient for the type 1 IFN receptor (Ifnar1À/À) were crossed with mice predisposed to developing aggressive fibromatosis tumors (Apc/Apc1638N), a significant decrease in aggressive fibromatosis tumor formation was observed compared with littermate controls, showing a novel role for type 1 IFN signaling in promoting tumor formation. Type 1 IFN activation inhibits cell proliferation but does not alter cell apoptosis or the level of B-catenin-mediated TCF-dependent transcriptional activation in aggressive fibromatosis cell cultures. Thus, these changes cannot explain our in vivo results. Intriguingly, Ifnar1À/À mice have smaller numbers of mesenchymal progenitor cells compared with littermate controls, and treatment of aggressive fibromatosis cell cultures with IFN increases the proportion of cells that exclude Hoechst dye and sort to the side population, raising the possibility that type 1 IFN signaling regulates the number of precursor cells present that drive aggressive fibromatosis tumor formation and maintenance. This study identified a novel role for IFN type 1 signaling as a positive regulator of neoplasia and suggests that IFN treatment is a less than optimal therapy for this tumor type. [Cancer Res 2007;67(15):7124-31]

show abstract

“…The only factor for recurrence-free follow-up seems to be negative margins [16,30,31]. On the other hand, some authors claim that recurrence seems to be independent of the margin status [33,33], and a margin of less than 1mm did not adversely affect outcome when compared with more generous margins.…”

Section: Chemotherapy (Vincristin/aktinomycin Cyclophosphamid Ormentioning

confidence: 99%

Aggressive fibromatosis of the head and neck: a new classification based on a literature review over 40 years (1968–2008)

Kruse

Luebbers

Grätz

et al. 2010

Oral Maxillofac Surg

View full text Add to dashboard Cite

Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin

Cited by 59 publications

References 61 publications

Robotic-Assisted Distal Pancreatectomy for a Pancreatic Desmoid Tumor: A Case Report and Review of the Literature

Robotic-Assisted Distal Pancreatectomy for a Pancreatic Desmoid Tumor: A Case Report and Review of the Literature

IFN-β Signaling Positively Regulates Tumorigenesis in Aggressive Fibromatosis, Potentially by Modulating Mesenchymal Progenitors

Aggressive fibromatosis of the head and neck: a new classification based on a literature review over 40 years (1968–2008)

Contact Info

Product

Resources

About